The abstract is read at the publisher; the summary is JClub's.
Delivering drugs to the brain is now limited less by blood-brain barrier crossing and more by achieving cell- and region-specific delivery within a dynamically changing neurovascular unit to target neurodegeneration.
- Why it matters: Even when therapeutics reach the brain, neurodegeneration requires action in the correct cells and locations, and delivery must account for neurovascular changes over time.
- What they did: The work frames brain drug delivery as a precision problem, emphasizing targeting the right cells and regions while considering the dynamic state of the neurovascular unit.
- The result: It implies therapeutic delivery systems should be designed around cellular precision and neurovascular context to better enable neurodegeneration targeting.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.